Cardiovascular Drugs Practice Questions

Q: In congestive cardiac failure, which of the following is NOT used?

Trimetazidine. **Explanation:** The management of Congestive Cardiac Failure (CCF) focuses on reducing preload, afterload, and inhibiting maladaptive neurohumoral remodeling. **Why Trimetazidine is the correct answer:** Trimetazidine is a **pFOX (partial fatty acid oxidation) inhibitor**. It shifts myocardial metabolism from fatty acid oxidation to glucose oxidation, which requires less oxygen to produce ATP. While it is an effective anti-anginal agent used in stable coronary artery disease, it is **not** a standard treatment for the acute or chronic management of cardiac failure itself. It does not provide the hemodynamic benefits (like diuresis or vasodilation) required in CCF. **Analysis of Incorrect Options:** * **Spironolactone:** An aldosterone antagonist (MRA) that is a cornerstone in CCF management (NYHA Class II-IV). It prevents myocardial fibrosis and reduces mortality. * **Nitrates:** These are venodilators that reduce **preload**. They are particularly useful in acute heart failure and in combination with Hydralazine (especially in African American populations) to reduce mortality. * **Nesiritide:** A recombinant **B-type Natriuretic Peptide (BNP)**. It causes vasodilation and natriuresis, used primarily in the management of acutely decompensated heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs reducing mortality in CCF:** ACE inhibitors/ARBs, Beta-blockers (Carvedilol, Metoprolol succinate, Bisoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan). * **Digoxin:** Improves symptoms and reduces hospitalization but does **not** reduce mortality in CCF. * **Trimetazidine Side Effect:** Can cause or worsen **Parkinsonian symptoms** (tremors, rigidity) due to its effect on the nigrostriatal pathway.

Q: What effect does a lower dose of dopamine have on a patient in cardiogenic shock?

Urine output. ### Explanation Dopamine is a unique catecholamine because its effects are strictly **dose-dependent**. Understanding these dose ranges is a high-yield concept for NEET-PG. **1. Why "Urine Output" is correct:** At **low doses (0.5–2 µg/kg/min)**, dopamine primarily acts on **D1 receptors** located in the renal, mesenteric, and coronary vascular beds. Activation of D1 receptors causes vasodilation, specifically increasing renal blood flow and the glomerular filtration rate (GFR). This results in increased **urine output** (diuresis) and sodium excretion (natriuresis). This is often referred to as the "renal dose" of dopamine. **2. Analysis of Incorrect Options:** * **Cardiac Output (Option A):** This is the primary effect of **medium doses (2–10 µg/kg/min)**. At this range, dopamine stimulates **β1-adrenergic receptors** in the heart, increasing myocardial contractility (inotropy) and stroke volume. * **Heart Rate (Option C):** While β1 stimulation at medium doses can increase heart rate (chronotropy), it is not the specific effect of a *low* dose. Tachycardia is often a limiting side effect at higher doses. * **Blood Pressure (Option D):** Significant increases in blood pressure occur at **high doses (>10 µg/kg/min)**. At this level, dopamine stimulates **α1-adrenergic receptors**, leading to systemic vasoconstriction and increased peripheral resistance. **3. Clinical Pearls for NEET-PG:** * **The "D-B-A" Rule:** Remember the sequence of receptor activation as dose increases: **D**opaminergic (Low) → **B**eta (Medium) → **A**lpha (High). * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Current Status:** While "renal dose" dopamine increases urine output, clinical trials (like the SOAP II trial) have shown it does not necessarily prevent acute renal failure or improve mortality, leading to a preference for Norepinephrine in many shock scenarios.

Q: A patient developed acute congestive heart failure and was put on digitalis therapy. ECG of this patient revealed the presence of ventricular extrasystoles. Which of the following drugs can be administered safely to this patient in order to counteract this arrhythmia?

Lignocaine. **Explanation:** Digitalis (Digoxin) toxicity commonly manifests as cardiac arrhythmias, with **ventricular extrasystoles** (premature ventricular contractions) being one of the earliest and most frequent signs. This occurs due to increased intracellular calcium leading to delayed after-depolarizations (DADs). **Why Lignocaine is the Correct Choice:** Lignocaine (Lidocaine) is a **Class IB anti-arrhythmic** drug and is the drug of choice for digitalis-induced ventricular arrhythmias. It works by blocking activated and inactivated sodium channels, effectively suppressing ventricular ectopic foci without significantly depressing AV conduction or myocardial contractility. It has a high degree of safety in the setting of digitalis toxicity. **Why Other Options are Incorrect:** * **Quinidine (Option B):** It is strictly contraindicated. Quinidine reduces the renal and biliary clearance of Digoxin and displaces it from tissue binding sites, leading to a dangerous rise (doubling) in plasma Digoxin levels, worsening the toxicity. * **Atropine (Option C):** While Atropine is used to treat digitalis-induced bradycardia or AV block, it has no role in managing ventricular extrasystoles. * **Amiodarone (Option D):** Like Quinidine, Amiodarone can increase Digoxin levels by interfering with its excretion and is generally avoided in acute digitalis-induced ventricular arrhythmias. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Digitalis Toxicity:** Digoxin-specific Fab fragments (Digibind) is the definitive antidote. * **Electrolyte Imbalance:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digitalis toxicity. * **ECG Sign of Toxicity:** Bigeminy (ventricular extrasystoles occurring every second beat) is a classic sign. * **ECG Sign of Digitalis Effect (Not Toxicity):** "Hockey stick" appearance or sagging ST-segment depression.

Q: Which drug is a potassium channel opener with anti-anginal activity?

Nicorandil. **Explanation:** **Nicorandil (Option A)** is the correct answer because it possesses a unique dual mechanism of action. It acts as a **Potassium channel opener** (specifically ATP-sensitive $K^+$ channels) and a **Nitrate-like vasodilator**. By opening $K^+$ channels in vascular smooth muscle, it causes hyperpolarization, leading to arterial vasodilation (reducing afterload). Its nitrate moiety increases cGMP, causing venous vasodilation (reducing preload). This dual action improves coronary blood flow and reduces myocardial oxygen demand, making it effective in stable angina. **Incorrect Options:** * **Dipyridamole (Option B):** This is a phosphodiesterase inhibitor and adenosine uptake inhibitor. While it is a vasodilator, it is notorious for causing **"Coronary Steal Phenomenon"** and is primarily used in pharmacological stress testing or as an antiplatelet agent. * **Dofetilide (Option C):** This is a **Class III Antiarrhythmic** drug. It acts by *blocking* potassium channels (specifically the $I_{Kr}$ current) to prolong the action potential duration, rather than opening them. * **Amiodarone (Option D):** A broad-spectrum Class III Antiarrhythmic that blocks $K^+$, $Na^+$, and $Ca^{2+}$ channels, and has anti-adrenergic effects. Like Dofetilide, it is a $K^+$ channel **blocker**. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effect:** A highly specific side effect of Nicorandil is **painful mucosal ulcerations** (oral, anal, or GI ulcers). * **Preconditioning:** Nicorandil mimics "ischemic preconditioning," providing a cardioprotective effect during episodes of ischemia. * **Contraindication:** Avoid use with PDE-5 inhibitors (e.g., Sildenafil) due to the risk of severe hypotension.

Q: Aprindine is a ....... antiarrhythmic drug?

Class IB. **Explanation:** Antiarrhythmic drugs are categorized using the **Vaughan-Williams classification**, which is based on their primary mechanism of action on the cardiac action potential. **Why Class IB is correct:** **Aprindine** belongs to **Class IB** sodium channel blockers. Like Lidocaine and Mexiletine, Class IB drugs bind to sodium channels in the inactivated state. They are characterized by rapid onset and offset kinetics. They slightly shorten the action potential duration (APD) and the effective refractory period (ERP) in ventricular tissues, making them particularly useful for ventricular arrhythmias. **Why other options are incorrect:** * **Class IA (e.g., Quinidine, Procainamide):** These drugs moderately block sodium channels and also block potassium channels, leading to a prolonged action potential duration and QT interval. * **Class IC (e.g., Flecainide, Propafenone):** These are the most potent sodium channel blockers with slow dissociation kinetics. They significantly depress the rate of rise of the action potential (Phase 0) but have minimal effect on the duration of the action potential. * **Class IV (e.g., Verapamil, Diltiazem):** These are Calcium Channel Blockers (CCBs) that primarily act on the SA and AV nodes to slow conduction. **High-Yield NEET-PG Pearls:** * **Aprindine** has a narrow therapeutic index and is rarely used today due to side effects like agranulocytosis and neurological toxicity. * **Mnemonic for Class I:** **"Double Quarter Pounder"** (IA: Disopyramide, Quinidine, Procainamide), **"Lettuce, Mayo, Tomato, Apricot"** (IB: Lidocaine, Mexiletine, Tocainide, **Aprindine**), **"Fries Please"** (IC: Flecainide, Propafenone). * **Class IB** drugs are "selective" for ischemic or depolarized tissue, which is why they are effective post-MI.

Q: Which beta-blocker also possesses alpha-blocking activity?

Carvedilol. **Explanation:** The correct answer is **Carvedilol**. Beta-blockers are classified into three generations based on their receptor selectivity and additional properties [1]. Carvedilol is a **third-generation, non-selective beta-blocker** that also possesses **alpha-1 ($\alpha_1$) blocking activity** [2]. This dual action leads to peripheral vasodilation (via $\alpha_1$ blockade) alongside decreased heart rate and contractility (via $\beta$ blockade). This unique profile makes it particularly effective in managing chronic heart failure and hypertension, as it reduces afterload without causing reflex tachycardia [2]. **Analysis of Incorrect Options:** * **Atenolol:** A second-generation, **cardioselective ($\beta_1$)** blocker. It lacks $\alpha$-blocking activity and is primarily used for hypertension and angina. * **Pindolol:** A first-generation, non-selective beta-blocker characterized by **Intrinsic Sympathomimetic Activity (ISA)**. It acts as a partial agonist, causing less bradycardia at rest. * **Nadolol:** A first-generation, **non-selective** beta-blocker with a long half-life. It does not possess $\alpha$-blocking properties. **High-Yield Clinical Pearls for NEET-PG:** * **Mixed $\alpha$ and $\beta$ Blockers:** Remember the duo **Labetalol** and **Carvedilol** [2], [3]. Labetalol is the drug of choice for hypertension in pregnancy (preeclampsia) [3]. * **Third-Generation Blockers:** These are "vasodilatory" beta-blockers. Examples include **Carvedilol** ($\alpha_1$ block), **Labetalol** ($\alpha_1$ block), and **Nebivolol** (via Nitric Oxide release). * **Heart Failure Benefit:** Carvedilol, Metoprolol succinate, and Bisoprolol are the three beta-blockers proven to reduce mortality in chronic heart failure.

Question 1

What is the mechanism of action of Ezetimibe?

Accepted Answer

Interferes with absorption of cholesterol by inhibiting NPC1L1

Answer

Interferes with absorption of bile acids

Answer

Inhibits CETP

Answer

Inhibitor of PPAR-α

Question 2

Lignocaine is useful for the treatment of which of the following conditions?

Accepted Answer

Digitalis-induced ventricular extrasystoles

Answer

Atrial fibrillation

Answer

Paroxysmal supraventricular tachycardia

Answer

All of the above

Question 3

In congestive cardiac failure, which of the following is NOT used?

Accepted Answer

Trimetazidine

Answer

Spironolactone

Answer

Nitrates

Answer

Nesiritide

Question 4

All of the following are complications of streptokinase, except?

Accepted Answer

Joint pain

Answer

Intracranial bleed

Answer

Fever

Answer

Anaphylaxis

Question 5

What effect does a lower dose of dopamine have on a patient in cardiogenic shock?

Accepted Answer

Urine output

Answer

Cardiac output

Answer

Heart rate

Answer

Blood pressure

Question 6

A patient developed acute congestive heart failure and was put on digitalis therapy. ECG of this patient revealed the presence of ventricular extrasystoles. Which of the following drugs can be administered safely to this patient in order to counteract this arrhythmia?

Accepted Answer

Lignocaine

Answer

Quinidine

Answer

Atropine

Answer

Amiodarone

Question 7

Which drug is a potassium channel opener with anti-anginal activity?

Accepted Answer

Nicorandil

Answer

Dipyridamole

Answer

Dofetilide

Answer

Amiodarone

Question 8

Aprindine is a ....... antiarrhythmic drug?

Accepted Answer

Class IB

Answer

Class IA

Answer

Class IC

Answer

Class IV

Question 9

Which beta-blocker also possesses alpha-blocking activity?

Accepted Answer

Carvedilol

Answer

Atenolol

Answer

Pindolol

Answer

Nadolol

Question 10

Which of the following drugs are used in the management of heart failure?

Accepted Answer

Carvedilol

Answer

ACE inhibitors

Answer

Hydralazine

Answer

Chlorthalidone

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?